Get the Stockscreener App
8.03
0.74%
-0.06
Olema Pharmaceuticals Inc stock is traded at $8.03, with a volume of 1.14M.
It is down -0.74% in the last 24 hours and down -3.83% over the past month.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
See More
Previous Close:
$8.09
Open:
$8.25
24h Volume:
1.14M
Relative Volume:
1.07
Market Cap:
$551.13M
Revenue:
-
Net Income/Loss:
$-96.66M
P/E Ratio:
-3.7349
EPS:
-2.15
Net Cash Flow:
$-83.73M
1W Performance:
-14.21%
1M Performance:
-3.83%
6M Performance:
+57.45%
1Y Performance:
-31.48%
1-Day Range:
$7.94
$8.33
1-Week Range:
$6.65
$8.48
52-Week Range:
$2.86
$13.51
Olema Pharmaceuticals Inc Stock (OLMA) Company Profile
Name
Olema Pharmaceuticals Inc
Sector
Industry
Phone
(415) 651-3316
Address
780 BRANNAN STREET, SAN FRANCISCO
Compare OLMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OLMA
Olema Pharmaceuticals Inc
|
8.03 | 555.25M | 0 | -96.66M | -83.73M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Olema Pharmaceuticals Inc Stock (OLMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-25 | Initiated | Guggenheim | Buy |
| Aug-12-25 | Reiterated | Citigroup | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Jan-30-24 | Initiated | Citigroup | Buy |
| Jul-21-23 | Initiated | Oppenheimer | Outperform |
| May-05-23 | Initiated | CapitalOne | Overweight |
| Feb-22-23 | Initiated | Credit Suisse | Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Jun-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-28-22 | Initiated | H.C. Wainwright | Neutral |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Dec-14-20 | Initiated | Canaccord Genuity | Buy |
| Dec-14-20 | Initiated | Cowen | Outperform |
| Dec-14-20 | Initiated | JP Morgan | Overweight |
| Dec-14-20 | Initiated | Jefferies | Buy |
View All
Olema Pharmaceuticals Inc Stock (OLMA) Latest News
Olema Pharmaceuticals (NASDAQ:OLMA) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Olema Pharmaceuticals Inc. stock momentum explained2025 Fundamental Recap & Fast Gain Swing Trade Alerts - newser.com
Will Olema Pharmaceuticals Inc. stock rally after Fed decisionsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Has Olema Pharmaceuticals Inc. found a price floor2025 Stock Rankings & Daily Stock Momentum Reports - newser.com
Will Olema Pharmaceuticals Inc. continue its uptrend2025 Investor Takeaways & Technical Buy Zone Confirmation - newser.com
How sustainable is Olema Pharmaceuticals Inc. stock dividend payout2025 Trading Recap & Daily Profit Maximizing Tips - newser.com
Olema Pharmaceuticals Inc Stock Analysis and ForecastSector ETF Performance & Rapid Portfolio Trading - earlytimes.in
Why Olema Pharmaceuticals Inc. stock is in analyst buy zone2025 Breakouts & Breakdowns & Risk Managed Investment Strategies - newser.com
Can Olema Pharmaceuticals Inc. stock double in next 5 yearsMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
Setup Watch: Will Olema Pharmaceuticals Inc. stock rally after Fed decisions2025 Stock Rankings & Low Risk High Reward Trade Ideas - nchmf.gov.vn
Olema Pharmaceuticals (OLMA) Stock Analysis: A 197.62% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Using flow based indicators on Olema Pharmaceuticals Inc.July 2025 Volume & Smart Allocation Stock Reports - newser.com
Visual trend scoring systems applied to Olema Pharmaceuticals Inc.2025 Dividend Review & Long-Term Growth Portfolio Plans - newser.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 7.3%What's Next? - MarketBeat
Olema Pharmaceuticals: Tapping The Brakes (Rating Downgrade) (NASDAQ:OLMA) - Seeking Alpha
Olema Pharmaceuticals Reports Positive Phase 1b/2 Trial Results - TipRanks
Olema Pharmaceuticals, Inc. Presents New Data from Phase 1b/2 Trial of Palazestrant - TradingView
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap DownHere's Why - MarketBeat
Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector - MarketScreener
Olema Pharmaceuticals (OLMA) Shares Drop Following Trial Data - GuruFocus
Olema Pharmaceuticals Inc Stock (OLMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):